This content is in French.
HBsAg and immunity: a barrier or an ally against hepatitis B?
13 février 2025
#InfectiousDiseases #Hepatitis #HepatitisB #Immunity #Immunotherapy #Virus
Chronic hepatitis B (HBV) is a persistent viral infection affecting more than 300 million people worldwide. Despite therapeutic advancements, achieving functional cure remains a challenging goal, as current treatments only control viral replication without completely eradicating the infection. One of the main obstacles to this cure is the hepatitis B surface antigen (HBsAg), a protein produced in large quantities by infected cells. Studies suggest that this antigen plays a key role in viral evasion by disrupting the immune response, although the precise mechanisms involved remain unclear.
Chronic hepatitis B (HBV) is a persistent viral infection affecting more than 300 million people worldwide. Despite therapeutic advancements, achieving functional cure remains a challenging goal, as current treatments only control viral replication without completely eradicating the infection. One of the main obstacles to this cure is the hepatitis B surface antigen (HBsAg), a protein produced in large quantities by infected cells. Studies suggest that this antigen plays a key role in viral evasion by disrupting the immune response, although the precise mechanisms involved remain unclear.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Beudeker, B. J., et al. (2024). Association of HBsAg levels with differential gene expression in NK, CD8 T, and memory B cells in treated patients with chronic HBV. JHEP Reports, 6(2), 100980
View the source
